ProAxsis specialises in the development and commercialisation of in vitro diagnostic laboratory assays and point–of–care tests designed to measure active protease biomarkers of disease.
CV6 Therapeutics is dedicated to the development of novel innovative therapeutics to improve the lives of patients with cancer and inflammatory diseases.